Evaluation of Real-World Total Healthcare Costs Difference Between Subcutaneous and Intravenous Formulations of Pertuzumab and Trastuzumab in HER2+ Breast Cancer Patients
Author(s)
Achal Patel, PhD1, Emma Behan, Dr1, Anita Fung, Dr1, Ibrahim Abbass, RPh, PhD2;
1Genentech Inc., South San Francisco, CA, USA, 2Genentech Inc., Principal Health Economist, South San Francisco, CA, USA
1Genentech Inc., South San Francisco, CA, USA, 2Genentech Inc., Principal Health Economist, South San Francisco, CA, USA
OBJECTIVES: The subcutaneous (SQ) formulations of anticancer drugs may reduce the need for vascular access devices and facilitate care in lower-resource settings, potentially lowering total healthcare costs (THCC). This study compares the average monthly THCC of SQ fixed-dose combination [FDC] Pertuzumab and Trastuzumab (PH) with intravenous (IV) PH among patients with breast cancer (BC) over a one-year period or a maximum of 18 cycles.
METHODS: We retrospectively analyzed data from adult women with HER2+ BC identified between 01/01/2021 and 12/31/2023 in the IQVIA PharMetricsⓇ Plus database. Patients were grouped into neoadjuvant (NEO), adjuvant-only (ADJ), and metastatic (mBC) cohorts. Targeted maximum likelihood estimation with machine learning was used to calculate average monthly THCC differences across the three cohorts adjusting for age, payer type, plan type, CCI, baseline total cost.
RESULTS: A total of 1,871 patients were included , with 70.8% in the NEO cohort, 16.5% in the ADJ cohort, and 12.7% in the mBC cohort. In the NEO cohort (1,325 patients) , 92.5% received PH IV, and 7.5% PH FDC. In the ADJ cohort (n=309), 89% received PH IV and 11% PH FDC. Among mBC patients (n= 237), 92.4% received PH IV, while 7.6% received PH FDC. Average monthly THCC were lower for the PH FDC compared to PH IV in all cohorts, with a monthly cost difference of $3,346 (95%CI=$2,318, $4,376) in the NEO, $5,227 ($3,349, $7,107) in the ADJ, and $5,585 ($3,485, $7,684) in the mBC cohorts.
CONCLUSIONS: PH FDC (SQ) is associated with significantly lower average monthly THCC compared to PH IV across different BC cohorts, with projected potential annual savings ranging from $59,637 in eBC (4 NEO + 14 ADJ cycles) to $62,724 in mBC (18 cycles)
METHODS: We retrospectively analyzed data from adult women with HER2+ BC identified between 01/01/2021 and 12/31/2023 in the IQVIA PharMetricsⓇ Plus database. Patients were grouped into neoadjuvant (NEO), adjuvant-only (ADJ), and metastatic (mBC) cohorts. Targeted maximum likelihood estimation with machine learning was used to calculate average monthly THCC differences across the three cohorts adjusting for age, payer type, plan type, CCI, baseline total cost.
RESULTS: A total of 1,871 patients were included , with 70.8% in the NEO cohort, 16.5% in the ADJ cohort, and 12.7% in the mBC cohort. In the NEO cohort (1,325 patients) , 92.5% received PH IV, and 7.5% PH FDC. In the ADJ cohort (n=309), 89% received PH IV and 11% PH FDC. Among mBC patients (n= 237), 92.4% received PH IV, while 7.6% received PH FDC. Average monthly THCC were lower for the PH FDC compared to PH IV in all cohorts, with a monthly cost difference of $3,346 (95%CI=$2,318, $4,376) in the NEO, $5,227 ($3,349, $7,107) in the ADJ, and $5,585 ($3,485, $7,684) in the mBC cohorts.
CONCLUSIONS: PH FDC (SQ) is associated with significantly lower average monthly THCC compared to PH IV across different BC cohorts, with projected potential annual savings ranging from $59,637 in eBC (4 NEO + 14 ADJ cycles) to $62,724 in mBC (18 cycles)
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE253
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology